PRAECIS PHARMACEUTICALS INCORPORATED To Announce Fourth Quarter and Year End 2005 Financial Results on Friday, February 3, 2006

PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ:PRCS),
today announced that it will report Fourth Quarter and Year End 2005
financial results on Friday, February 3, 2006, before the financial
markets open. Company management will host a conference call beginning
at 9:00 a.m., EST, with members of the investment community.
   The Company's conference call may be accessed live by visiting
PRAECIS' website at http://www.praecis.com under "Investors" and
"Webcast Live." Interested parties also may listen to a replay of the
call beginning Friday, February 3, at 12:00 Noon, EST, until midnight
Friday, February 10, by calling 888-203-1112 or 719-457-0820, and
entering the passcode 703121.

   PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical
company focused on the discovery and development of innovative
therapies that either address unmet medical needs or offer
improvements over existing therapies. PRAECIS has a novel MetAP-2
inhibitor, PPI-2458, in clinical development for non-Hodgkin's
lymphoma and solid tumors, as well as an innovative drug discovery
technology, DirectSelect(TM), which enables the generation and
practical use of ultra-large libraries for the discovery of orally
active compounds for drug development. PRAECIS has received approval
to market Plenaxis(R) in both the United States and Germany.